Trial Details
RecruitingBasic Information
| Clinical ID | c5680 |
|---|---|
| Identifier | NL-OMON54535 |
| Trial Title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis . - M16-066 |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NULL |
|---|---|
| Conditions | form of inflammatory Bowel Disease (IBD) Ulcerative Colitis;10017969 |
| Interventions | Subjects receive once every eight weeks SC risankizumab or SC placebo. They receive this medication until the end of the study or till premature discontinuation. For subjects requiring rescue therapy, they will receive once risankizumab IV |
Participant Information
| Sponsor | AbbVie B.V. |
|---|---|
| City | NULL |
| Country/Region | Netherlands |
Enrollment Criteria
| Sex Requirement | NOT SPECIFIED |
|---|---|
| Age Requirement | ADULT, ELDER, OLDER_ADULT |
Study Design
| Study Type | Interventional |
|---|---|
| Phase | NULL |
Time Information
| Start Date | NULL |
|---|---|
| Primary Completion Date | NULL |
| Completion Date | NULL |